Kovack Advisors Inc. Buys 2,063 Shares of Merck & Co., Inc. (NYSE:MRK)

Kovack Advisors Inc. boosted its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 8.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,896 shares of the company’s stock after purchasing an additional 2,063 shares during the quarter. Kovack Advisors Inc.’s holdings in Merck & Co., Inc. were worth $3,417,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Norges Bank acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $3,108,366,000. Wellington Management Group LLP grew its stake in shares of Merck & Co., Inc. by 6.7% during the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock worth $8,487,472,000 after acquiring an additional 5,196,914 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock valued at $3,966,029,000 after acquiring an additional 4,731,152 shares in the last quarter. Bank of Nova Scotia raised its position in shares of Merck & Co., Inc. by 352.2% in the 4th quarter. Bank of Nova Scotia now owns 3,144,632 shares of the company’s stock valued at $342,814,000 after purchasing an additional 2,449,211 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado boosted its stake in Merck & Co., Inc. by 29,914.1% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 2,410,732 shares of the company’s stock worth $262,818,000 after purchasing an additional 2,402,700 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MRK. Berenberg Bank raised their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a research note on Tuesday, June 18th. Truist Financial boosted their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Wells Fargo & Company lifted their target price on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Finally, Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price on the stock. in a research report on Monday, March 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $133.00.

View Our Latest Research Report on MRK

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $125.85 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The stock has a market capitalization of $318.75 billion, a price-to-earnings ratio of 139.83, a PEG ratio of 2.43 and a beta of 0.38. The firm’s 50 day simple moving average is $129.33 and its 200-day simple moving average is $124.71. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $134.63.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.21 billion. During the same period in the prior year, the firm posted $1.40 earnings per share. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 8.62 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be paid a $0.77 dividend. The ex-dividend date is Monday, June 17th. This represents a $3.08 annualized dividend and a dividend yield of 2.45%. Merck & Co., Inc.’s dividend payout ratio is presently 342.22%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.